Insulin secretion in the beta cell: from glucose to granule

How does glucose become an electrical signal?

After a meal, blood glucose climbs out of its fasting range of about 70 to 100 mg/dL.^[1][13] Within minutes the beta cells of the pancreas answer by releasing insulin, although a beta cell has no eyes and no taste buds.^[1][2]

This lesson on insulin secretion in the beta cell traces how a sugar molecule becomes an electrical signal, and shows exactly where sulfonylurea drugs act.

The beta cell and the KATP channel

Beta cells sit in the islets of Langerhans of the pancreas.^[1][2] At rest the membrane stays negative, because potassium leaks out through open ATP-sensitive potassium channels, called KATP channels.^[2][3]

Each channel is built from four pore subunits, Kir6.2, and four regulatory subunits, the sulfonylurea receptor 1 (SUR1).^[3][4] Remember the name SUR1: it is where the drugs bind.

Open channels let potassium leave and keep the cell at rest. When ATP rises, the channels close, and that single event is what turns a metabolic signal into an electrical one.^[2][3]

Glucose-stimulated insulin secretion in six steps

1. Glucose enters the beta cellIt crosses through a glucose transporter, taught as GLUT2 in the exam, though human beta cells also use GLUT1.^[5]
2. Glucokinase phosphorylates itThis is the first step of glycolysis. Glucokinase has a low affinity for glucose, so its rate follows the blood level, which makes it the cell's glucose sensor.^[6]
3. ATP risesGlycolysis and the mitochondria make ATP, so the ATP to ADP ratio rises.^[2][3]
4. The KATP channel closesRising ATP closes the channel. Potassium can no longer leave, so the membrane depolarises.^[2][3]
5. Calcium floods inDepolarisation opens L-type voltage-gated Ca²⁺ channels.^[2][3]
6. Insulin granules are releasedThe rise in Ca²⁺ triggers exocytosis of insulin granules.^[2][3]

So the chain is: glucose, ATP, channel closed, depolarised, calcium in, insulin out.

The glucose transporter and glucokinase are the entry and the sensor: the more glucose in the blood, the faster glucokinase works, and the more ATP the cell makes. Everything after that is the channel and the ions.^[5][6]

Biphasic release and amplifying signals

Release is biphasic: a fast first phase, then a slower, sustained second phase.^[2][7]

The first phase runs through the KATP-dependent chain above; in the sustained phase, that same trigger is gradually augmented by mechanisms that do not depend on the KATP channel.^[2]

Other signals amplify this response without replacing it. GLP-1 raises cyclic AMP, and amino acids and fatty acids add their own amplifying signals.^[2]

Sulfonylureas: closing the channel without glucose

Sulfonylureas, such as glyburide (called glibenclamide outside the US), glimepiride and tolbutamide, bind the SUR1 subunit.^[3][4] They close the channel by a route that does not need ATP, so the cell is pushed towards release even when glucose is low or normal.^[4]

That is why hypoglycaemia is their signature adverse effect.^[8][9] They also need beta cells that still make insulin.

Diazoxide and neonatal diabetes: the opposite and the proof

The opposite drug is diazoxide, which opens the KATP channel, keeps the cell resting and lowers insulin release.^[10][11]

One more clue that this is the real mechanism: activating mutations in the KATP channel genes cause neonatal diabetes, and many of those patients respond to a sulfonylurea.^[4][12]

Put the two drugs side by side and the logic of the channel is clear: closing it pushes the cell towards release, opening it holds the cell at rest.^[3][10]